AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAR 7 - (NewsRx.com & NewsRx.net) -- A study in the February 2002 issue of the Journal of Clinical Oncology shows that Femara (2.5 mg o.d.) more effectively inhibits total body aromatization and suppresses plasma estrogen levels compared with anastrozole (1 mg o.d.).
The randomized study examined the ability of Femara to inhibit total body aromatization and suppress plasma estrogen levels in 12 postmenopausal women with metastatic breast cancer compared with Arimidex (anastrozole). The differences between the two drugs in inhibiting total body aromatization (ovaries excepted) were statistically significant as was the suppression of two of the three major estrogens.
"We know that hormone sensitive breast cancers rely on estrogen for growth, and in this study, Femara was shown to be a more effective inhibitor of total body aromatization and suppressor of plasma estrogen levels as compared to anastrozole," said Per Eystein Lonning, professor of Oncology, Haukeland University Hospital, Norway.
The primary objective of the study was to compare the effects of the nonsteroidal aromatase inhibitors Femara and anastrozole on total body aromatization (the capacity of the whole body to produce estrogens) and plasma estrogen levels.
The trial was a randomized, crossover study of 12 postmenopausal women with metastatic breast cancer whose disease was suitable for treatment with an aromatase inhibitor. Patients were treated sequentially with anastrozole 1 mg followed by Femara 2.5 mg once daily (and vice versa), each ...
Source: HighBeam Research, Study finds letrozole tablets more effective than anastrozole in...